[{"orgOrder":0,"company":"Icon Plc","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FINLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tasipimidine","moa":"Alpha-2A adrenergic receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Tolmar","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"15","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MB-CART2019.1","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MB-CART2019.1","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Actinogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Neurology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Actinogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"9","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"XmAb20717","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"XmAb22841","moa":"Cytotoxic T-lymphocyte protein 4 (CTLA-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Golden Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imgatuzumab","moa":"Epidermal growth factor receptor erbB1 | Low affinity immunoglobulin gamma Fc region receptor III-A","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase IV","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"11","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Oculis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Oculis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Neurology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ARC-520","moa":"HBV mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"XmAb7195","moa":"IgE receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"XmAb23104","moa":"Inducible T-cell costimulator (ICOS)","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Nordic Nanovector","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody-drug Conjugate","year":"2013","type":"Inapplicable","leadProduct":"Tetulomab Tetraxetan Lu-177","moa":"monoclonal antibodies: mouse","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Nordic Nanovector","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Tetulomab Tetraxetan Lu-177","moa":"monoclonal antibodies: mouse","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"XmAb13676","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"XmAb14045","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"XmAb18087","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"XmAb18087","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PDCD1","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Stealth Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CS-7017","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CS-7017","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"AltruBio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALTB-268","moa":"PSGL-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Akros Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JTT-861","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"11","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Adaptimmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous ADP-A2M4CD8 Cell","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Etigilimab","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"7","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Diamyd Medical AB","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-7104.056","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Bone Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allob","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Adaptimmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Genetically Modified ADP-A2M4CD8 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Evergreen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"EG-009A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Evergreen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Evergreen Therapeutics"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Fervent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FP-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"IgPro20","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"JCXH-105","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"JCXH-221","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LEO 153339","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Monument Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MT1980","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Mediar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human Apolipoprotein(A) Kringle V","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XmAb27564","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Icon Plc \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ Icon Plc"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Rosenfeld, William E., M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Rosenfeld, William E., M.D.","highestDevelopmentStatusID":"9","companyTruncated":"Icon Plc \/ Rosenfeld, William E., M.D."},{"orgOrder":0,"company":"Icon Plc","sponsor":"Iman Almansour","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S.opt.FL COVID-19 pDNA Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Iman Almansour","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Iman Almansour"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Dariush Elahi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VTC-G15","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Dariush Elahi","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Dariush Elahi"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Danisco","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Danisco"}]
Find Clinical Drug Pipeline Developments & Deals by Icon Plc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
